Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action

Lancet

Volumn 355, Issue 9221, 2000, Pages 2125-2131

  Saleem, Azeem ^a   Yap, Jeff ^a   Osman, Safiye ^a   Brady, Frank ^a   Suttle, Benjamin ^b   Lucas, Sol V ^b   Jones, Terry ^a   Price, Pat M ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUORINE 18; FLUOROURACIL; URACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG RETENTION; DRUG TUMOR LEVEL; DRUG UPTAKE; ENZYME INACTIVATION; FEMALE; HALF LIFE TIME; HUMAN; IMAGING; ISOTOPE LABELING; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0034679322     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02380-1     Document Type: Article

References (27)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
2. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
3. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-06.
4. Ahmed FY, Johnston SJ, Cassidy J, et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumours. J Clin Oncol 1999; 17: 2439-45.
5. Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085-96.
6. 19F nuclear magnetic resonance spectroscopy. Cancer Res 1999; 59: 122-27.
7. Harte RJ, Matthews JC, O'Reilly SM, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999; 17: 1580-88.
8. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997; 57: 3415-23.
9. Brix G, Bellemann ME, Gerlach L, Haberkorn U. Intra- and extracellular fluorouracil uptake: assessment with contrast- enhanced metabolic F-19 MR imaging. Radiology 1998; 209: 259-67.
10. Liu M, Russell RL, Beigelman L, Handschumacher RE, Pizzorno G. beta-alanine and alpha-fluoro-beta-alanine concentrative transport in rat hepatocytes is mediated by GABA transporter GAT-2. Am J Physiol 1999; 276: G206-10.
11. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-79.
12. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992; 52: 1592-97.
13. Brown G, Brady F, Roberts AD, Osman S, Luthra SK, Price PM. Improved radio synthesis of 5-[18F]fluorouracil. J Labelled Compd Radiopharm 1999; 42: 533-35.
14. Amin JM, LeLacheur R, Harvan D, Morris D. Determination of fluoro-beta-alanine in human urine using liquid-liquid extraction and GC/MS/SIM. Pharm Res 1997; 14 (suppl): S-267.
15. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID. Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 1982; 257: 8171-76.
16. Wolf W, Albright MJ, Silver MS, Weber H, Reichardt U, Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging 1987; 5: 165-69.
17. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223-28.
18. Etienne MC, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70.
19. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
20. Davis ST, Joyner SS, Baccanari DP, Spector T. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 1994; 48: 233-36.
21. Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993; 46: 2243-48.
22. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-12.
23. Jessen H, Roigaard H, Jacobsen C. Uptake of neutral alpha- and beta-amino acids by human proximal tubular cells. Biochim Biophys Acta 1996; 1282: 225-32.
24. Sweeny DJ, Martin M, Diasio RB. N-chenodeoxycholyl-2-fluoro-beta-alanine: a biliary metabolite of 5- fluorouracil in humans. Drug Metab Dispos 1988; 16: 892-94.
25. 19F NMR spectrometry evidence for bile acid conjugates of alpha-fluoro- beta-alanine as the main biliary metabolites of antineoplastic fluoropyrimidines in humans. Drug Metab Dispos 1988; 16: 78-84.
26. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-41.
27. Baker SD, Diasiao RB, O'Reilly S, et al. Phase I and pharmacologic study of oral 5-FU on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000; 18: 915-26.